MAJIC looks at a drug called ruxolitinib to treat high risk polycythaemia vera (PV) and essential thrombocythaemia (ET).
PV and ET are myeloproliferative disorders which cause the bone marrow to make too many blood cells.
Doctors usually treat these conditions with hydroxycarbamide. Unfortunately some people can’t take hydroxycarbamide or the disease stops responding to it so new treatments are needed.
Ruxolitinib stops signals that cancer cells use to divide and grow.
The aims of this trial are to find out
- How well ruxolitinib works for people with PV and ET who can’t have hydroxycarbamide
- How safe it is
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
| Chief Investigator: Professor Claire Harrison |
|
| Sponsor: University of Birmingham |
|
| Funders: Bloodwise |
|
| Disease Site: Myeloproliferative Neoplams |
|
| Trial Type: Clinical Trial of an Investigational Medicinal Product |
|
| Status: Open |
|
| UKCRN Study ID: 11941 |
|
| Open to new sites? No |
|
| Recruitment start date: 09-Aug-2012 |
|
| Anticipated Recruitment end date: 31-Jul-2016 |
|
| CRCTU Trial Management Team: Haematology |
|
| Trial E-mail Address: MAJIC@trials.bham.ac.uk |
|